10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Thrombocytopenic Purpura
Conditions
Idiopathic Thrombocytopenic Purpura
Trial Timeline
Jan 1, 2012 → Aug 1, 2012
NCT ID
NCT01549054About 10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral is a phase 1 stage product being developed by Eisai for Idiopathic Thrombocytopenic Purpura. The current trial status is completed. This product is registered under clinical trial identifier NCT01549054. Target conditions include Idiopathic Thrombocytopenic Purpura.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01549054 | Phase 1 | Completed |
Competing Products
20 competing products in Idiopathic Thrombocytopenic Purpura